Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a …
R Sunagar, SD Prasad, R Ella, KM Vadrevu - Frontiers in Immunology, 2022 - frontiersin.org
Most if not all vaccine candidates developed to combat COVID-19 due to SARS-CoV-2
infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious …
infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious …
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
M Tiboni, L Casettari, L Illum - International journal of pharmaceutics, 2021 - Elsevier
It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular
administration designed to produce humoral and cell mediated immune responses …
administration designed to produce humoral and cell mediated immune responses …
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I …
Background Intranasal vaccination may induce protective local and systemic immune
responses against respiratory pathogens. A number of intranasal SARS-CoV-2 vaccine …
responses against respiratory pathogens. A number of intranasal SARS-CoV-2 vaccine …
Intranasal COVID-19 vaccines: From bench to bed
A Alu, L Chen, H Lei, Y Wei, X Tian, X Wei - EBioMedicine, 2022 - thelancet.com
Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization.
However, vaccination today failed to prevent the virus infection through the upper respiratory …
However, vaccination today failed to prevent the virus infection through the upper respiratory …
An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection
PA van der Ley, A Zariri, E van Riet… - Frontiers in …, 2021 - frontiersin.org
The development of more effective, accessible, and easy to administer COVID-19 vaccines
next to the currently marketed mRNA, viral vector, and whole inactivated virus vaccines is …
next to the currently marketed mRNA, viral vector, and whole inactivated virus vaccines is …
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
Multiple vaccines have recently been developed, and almost all the countries are presently
vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 …
vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 …
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Abstract Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines
display a superior advantage because the nasal mucosa is often the initial site of infection …
display a superior advantage because the nasal mucosa is often the initial site of infection …
[HTML][HTML] Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic
D Miteva, M Peshevska-Sekulovska… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Based on mucosal immunization to promote both mucosal and systemic immune responses,
next-generation coronavirus disease 2019 (COVID-19) vaccines would be administered …
next-generation coronavirus disease 2019 (COVID-19) vaccines would be administered …